Replimune (REPL) Income from Non-Controlling Interests (2019 - 2026)
Replimune (REPL) reported Income from Non-Controlling Interests of $510000.0 for Q1 2026, down 2.67% on a YoY basis from $524000.0 in Q1 2025, and down 0.78% sequentially from $514000.0 in Q4 2025.
Replimune (REPL) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Replimune (REPL) has 8 years of Income from Non-Controlling Interests data on file, last reported at $510000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Non-Controlling Interests fell 2.67% year-over-year to $510000.0; the trailing twelve-month figure through Mar 2026 stood at $886000.0 (down 59.13% YoY), and the FY2026 full-year result was $2.1 million, down 2.6% from the prior year.
- Income from Non-Controlling Interests declined to $510000.0 in Q1 2026, from $514000.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $1.2 million in Q3 2024 to a low of -$458000.0 in Q2 2023.
- A 5-year average of $316000.0 and a median of $514000.0 in 2025 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests sank 510.0% in 2022 and soared 467.76% in 2024, its largest moves.
- Tracing REPL's Income from Non-Controlling Interests over 5 years: stood at $548000.0 in 2022, then declined by 1.46% to $540000.0 in 2023, then decreased by 2.22% to $528000.0 in 2024, then dropped by 2.65% to $514000.0 in 2025, then slipped by 0.78% to $510000.0 in 2026.
- Business Quant data shows REPL's Income from Non-Controlling Interests at $510000.0 in Q1 2026, $514000.0 in Q4 2025, and $131000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Replimune | 970.73 Mn | 970.73 Mn | - | 510,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 510,000.00 |
| Dec 31, 2025 | 514,000.00 |
| Sep 30, 2025 | 131,000.00 |
| Jun 30, 2025 | -269,000.00 |
| Mar 31, 2025 | 524,000.00 |
| Dec 31, 2024 | 528,000.00 |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | -99,000.00 |
| Mar 31, 2024 | 537,000.00 |
| Dec 31, 2023 | 540,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | -458,000.00 |
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 548,000.00 |
| Sep 30, 2022 | 81,000.00 |
| Jun 30, 2022 | -244,000.00 |
| Mar 31, 2022 | 553,000.00 |
| Dec 31, 2021 | 555,000.00 |
| Sep 30, 2021 | 557,000.00 |
| Jun 30, 2021 | -40,000.00 |